Histology
Transitional Cell Carcinoma
CI-CAN-00001613Explore in graph →
253 active trials5 approved drugs22 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001613Explore in graph →
Clinical trials
734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (119)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04197089 | Biological Effect of Vitamin D in Patients With Urothelial Carcinoma(VitDURO) | completed | Phase 4 | 2 | Germans Trias i Pujol HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | terminated | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 29, 2022 |
| clinicaltrials |
| NCT05139134 | Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT00238420 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Jul 19, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05070039 | Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population | completed | N/A | 40 | Sohag UniversityOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT01524991 | First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | completed | Phase 2 | 36 | Hoosier Cancer Research NetworkOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | completed | Phase 2 | 200 | Noah Hahn, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | terminated | Phase 1 | 9 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03945084 | Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy | completed | Phase 2 | 58 | University of Turin, ItalyOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT04718948 | Multimodal Spectroscopy to Detect Urothelial Cancer in Urine | unknown | — | 500 | University of FlorenceOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04770974 | Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic | unknown | — | 200 | University of FlorenceOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival(RESECT) | terminated | Early Phase 1 | 2 | University Health Network, TorontoOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03062059 | The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence | unknown | Phase 2 | 134 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT03071328 | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers | completed | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05318339 | A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 8, 2022 | clinicaltrials |
| NCT04960956 | Glycosylation of Exosomes in Prostate and Urothelial Carcinoma | terminated | — | 13 | Indiana UniversityOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT02994758 | Development of Diagnostics and Treatment of Urological Cancers(DEDUCER) | unknown | N/A | 100 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02535650 | Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma | unknown | Phase 2 | 19 | Samsung Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04179110 | Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT05220124 | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma | unknown | Phase 4 | 190 | Tianjin Medical University Second HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04603846 | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT01093066 | Prospective Multicentric Evaluation of a Bladder Preservation Strategy(ReChiVe) | terminated | Phase 2 | 77 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT05160285 | Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma | unknown | Phase 2 | 29 | YULISUOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT03287050 | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma | terminated | Phase 2 | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04839510 | A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | unknown | Phase 2 | 58 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | terminated | Phase 1 | 2 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03548688 | Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer:(IDENTIFY) | completed | — | 11,059 | British Urology Researchers in Surgical TrainingOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT03179943 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | active not recruiting | Phase 2 | 21 | Fox Chase Cancer CenterOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03219775 | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma(TITAN-TCC) | unknown | Phase 2 | 169 | AIO-Studien-gGmbHOTHER | 2 | Nov 3, 2021 | clinicaltrials |
| NCT04730232 | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | unknown | Phase 2 | 63 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04432909 | A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up | unknown | — | 500 | Changhai HospitalOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT05043662 | UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis. | unknown | — | 110 | Changhai HospitalOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT05030077 | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | unknown | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | terminated | Phase 2 | 7 | Johannes Gutenberg University MainzOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT05027412 | En Bloc TURBT With Collins Loop vs Conventional TURBT(TURBT) | unknown | N/A | 80 | Hospital Universitario de FuenlabradaOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT03263039 | Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab(RESPONDER) | unknown | Phase 2 | 80 | Erasmus Medical CenterOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT03051373 | Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract | completed | Phase 2 | 108 | Chinese PLA General HospitalOTHER | 1 | Aug 9, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2022source: clinicaltrials